Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v14-EN | Version v13-FR | |
|---|---|---|
| Language | English | French |
| Date Updated | 2021-01-27 | 2020-11-24 |
| Drug Identification Number | 02239834 | 02239834 |
| Brand name | LUPRON DEPOT | LUPRON DEPOT |
| Common or Proper name | Lupron depot 11.25mg | Lupron depot 11.25mg |
| Company Name | ABBVIE CORPORATION | ABBVIE CORPORATION |
| Ingredients | LEUPROLIDE ACETATE | LEUPROLIDE ACETATE |
| Strength(s) | 11.25MG | 11.25MG |
| Dosage form(s) | POWDER FOR SUSPENSION, SUSTAINED-RELEASE | POWDER FOR SUSPENSION, SUSTAINED-RELEASE |
| Route of administration | INTRAMUSCULAR INTRAMUSCULAR | INTRAMUSCULAR INTRAMUSCULAR |
| Packaging size | 1 syringe (11.25mg) | 1 syringe (11.25mg) |
| ATC code | L02AE | L02AE |
| ATC description | HORMONES AND RELATED AGENTS | HORMONES AND RELATED AGENTS |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2020-07-14 | 2020-07-14 |
| Actual start date | 2020-07-14 | 2020-07-14 |
| Estimated end date | 2021-03-31 | 2021-01-29 |
| Actual end date | ||
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | We have been working with the manufacturing facility to increase production of LUPRON DEPOT and we will continue to distribute supplies as they become available. As production of LUPRON DEPOT continues to increase, we expect inventory of all formulations to stabilize shortly. AbbVie wishes to assure you that we are your primary source of accurate and timely information related to our inventory shortage. The shortage is temporary, and the safety and efficacy of LUPRON DEPOT were not compromised. | We have been working with the manufacturing facility to increase production of LUPRON DEPOT and we will continue to distribute supplies as they become available. As production of LUPRON DEPOT continues to increase, we expect inventory of all formulations to stabilize shortly. AbbVie wishes to assure you that we are your primary source of accurate and timely information related to our inventory shortage. The shortage is temporary, and the safety and efficacy of LUPRON DEPOT were not compromised. |
| Health Canada comments |